china.org.cn
New Mpox Vaccine Trial in Kenya
Kenya and US partner to trial new mpox vaccine amid surge in African cases.
English
China
HealthPublic HealthAfricaVaccineMpoxClinical Trial
Kenya Medical Research Institute (Kemri)Tonix PharmaceuticalsWorld Health OrganizationAfrica Centers For Disease Control And PreventionAfrican Union
Elijah SongokSeth Lederman
- Describe the characteristics of the TNX-801 vaccine.
- TNX-801 is a live-attenuated horsepox virus vaccine designed to be safer and better tolerated than older smallpox vaccines. Its stability at ambient temperatures and ease of administration make it suitable for large-scale vaccination programs.
- What is the current situation of mpox cases in Africa?
- The number of confirmed mpox cases in Africa has surged by over 545 percent in 2024 compared to 2023, with Central Africa being the most affected region.
- What are the key aspects of the planned clinical trial?
- The clinical trial will assess the safety, tolerability, and immunogenicity of TNX-801. Tonix Pharmaceuticals will sponsor the trial, while KEMRI will oversee its execution.
- What is the significance of the WHO's declaration regarding mpox in Africa?
- The World Health Organization declared the recent rise in mpox cases across Africa a Public Health Emergency of International Concern in August, highlighting the urgent need for effective vaccines like TNX-801.
- What is the main purpose of the partnership between KEMRI and Tonix Pharmaceuticals?
- Kenya Medical Research Institute (KEMRI) and Tonix Pharmaceuticals have partnered to conduct a Phase I clinical trial in Kenya for TNX-801, a new mpox vaccine.